Entrada Therapeutics (TRDA) EBT Margin: 2023-2025
Historic EBT Margin for Entrada Therapeutics (TRDA) over the last 3 years, with Sep 2025 value amounting to -2,693.93%.
- Entrada Therapeutics' EBT Margin fell 261272.00% to -2,693.93% in Q3 2025 from the same period last year, while for Sep 2025 it was -169.83%, marking a year-over-year decrease of 20535.00%. This contributed to the annual value of 31.55% for FY2024, which is 2217.00% up from last year.
- As of Q3 2025, Entrada Therapeutics' EBT Margin stood at -2,693.93%, which was down 22.38% from -2,201.28% recorded in Q2 2025.
- Over the past 5 years, Entrada Therapeutics' EBT Margin peaked at 61.03% during Q2 2024, and registered a low of -2,693.93% during Q3 2025.
- Its 3-year average for EBT Margin is -452.21%, with a median of -12.36% in 2023.
- Its EBT Margin has fluctuated over the past 5 years, first soared by 12,752bps in 2024, then plummeted by 261,272bps in 2025.
- Quarterly analysis of 3 years shows Entrada Therapeutics' EBT Margin stood at 22.08% in 2023, then slumped by 2,402bps to -1.94% in 2024, then crashed by 261,272bps to -2,693.93% in 2025.
- Its last three reported values are -2,693.93% in Q3 2025, -2,201.28% for Q2 2025, and -84.39% during Q1 2025.